Abstract
INTRODUCTION
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease which can progress to advanced fibrosis and cirrhosis [1, 2] . Hepatic fibrosis scores increase in 25% of patients despite corticosteroid therapy [3] .
Cirrhosis develops in 3% of treated patients per year [4] , and 1%-6% of individuals with cirrhosis develop hepatocellular carcinoma (HCC) [5, 6] . The prevention and reversal of hepatic fibrosis are key objectives in AIH, and the safe and reliable assessment of hepatic fibrosis is essential [7] . Histological evaluation is the gold standard for assessing hepatic fibrosis, but is suboptimal for monitoring disease progression due to its invasiveness, sampling error, and inter-observer variation [8] [9] [10] .
Noninvasive tests of hepatic fibrosis include laboratory and radiological tests, which have been validated in chronic viral hepatitis, but have not been rigorously assessed in AIH. Laboratory-based methods for staging liver fibrosis include the FibroTest ® [11] , the serum aspartate aminotransferase/platelet ratio index (APRI) [12] , the Fibrosis 4 (FIB-4) test [13] , and the enhanced liver fibrosis test [14] . These tests may detect cirrhosis, but their ability to reflect the stages of fibrosis in AIH is uncertain [15, 16] . The radiological tests of hepatic fibrosis include transient elastography by ultrasonography (TE), acoustic radiation force impulse (ARFI) imaging, and magnetic resonance elastography (MRE). TE has had high sensitivity and specificity for advanced stages of fibrosis and cirrhosis in chronic viral hepatitis, but its performance may differ in AIH [17, 18] . Serum alanine aminotransferase (ALT) levels greater than twice the normal limit have reduced the accuracy of TE in detecting early stages of fibrosis in chronic hepatitis B, and AIH is characterized by chronic inflammation of fluctuating intensity [19, 20] . Acute liver damage, as may occur in AIH, can also increase liver stiffness (LS) to levels suggestive of cirrhosis, only to resolve spontaneously with recovery [21] . Obesity can reduce the accuracy of TE and can be an important consequence of corticosteroid-treated AIH [22, 23] . The technical specifications of TE may also limit its utility in patients with ascites [24] . The correlation between LS and acute liver inflammation has expanded the clinical applications of TE to include the diagnosis of acute cellular rejection after liver transplantation [25] . Early studies with TE in AIH have reported that TE is an accurate and reliable non-invasive tool in assessing liver fibrosis in AIH [26, 27] . However one study by Hartl et al [26] and another case series by Romanque et al [28] demonstrated that inflammation impacts the accuracy of TE in evaluation of fibrosis. The same confounding factors that limit TE also affect the performance of ARFI. Although ARFI can differentiate normal from fibrosis secondary to chronic immune-mediated liver disease [29] , it has been outperformed by TE in diagnosing early fibrosis and distinguishing normal from fibrosis stage 1 [30] [31] [32] . The attributes that could support current diagnostic, prognostic, and therapeutic efforts to improve outcomes in AIH may reside in MRE.
MRE ( Figure 1 ) has had excellent performance parameters for all stages of fibrosis in diverse liver diseases [33] [34] [35] [36] [37] , and it has outperformed TE for staging liver fibrosis in patients with diverse chronic liver diseases [38] . Furthermore, MRE is unaffected by body habitus or hepatic steatosis [39, 40] and it can distinguish early from late stages of fibrosis and late stages of fibrosis from cirrhosis in liver diseases outside of AIH. It also may have prognostic implications via the assessment of splenic stiffness and the prediction of portal hypertension and esophageal varices [41] . Our goals were to determine the accuracy of MRE in the diagnosis of advanced hepatic fibrosis or cirrhosis in patients with AIH and to compare the findings to those of APRI, FIB-4, and magnetic resonance imaging (MRI).
MATERIALS AND METHODS

Patient selection
This retrospective study was approved by the Institution Review Board and informed consent was waived. We performed a search in the hospital database for patients who underwent MRE between [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] and had a diagnosis of AIH based on histology and by International AIH Group criteria [42] [43] [44] [45] . One hundred and thirty-eight patients met these criteria, of whom 62 were excluded as the interval between liver biopsy and MRE exceeded 3 mo. Another 40 patients were excluded due to overlapping features of another chronic liver disease. The final study group comprised of 36 patients. Of these, 17 patients were treatment-naïve and 19 patients had received immunosuppression treatment either at our institution or elsewhere. The treatment naïve patients had MRE performed within 3 mo of liver biopsy (mean 5 d; range 0 to 42 d). The treated patients had diagnosis of AIH and received treatment for variable period ranging from 1 mo to 25 years with a mean duration of 5.5 years. The time interval between liver biopsy and MRE in this group was 8.2 d (range 0 to 85 d).
Laboratory parameters
Laboratory tests performed within two weeks of MRE were recorded for each patient, and included international normalized ratio (INR), platelet count, serum aspartate amino transferase (AST) and ALT levels, AST/ALT ratio, AST to Platelet Ratio Index (APRI), and FIB-4 score. The APRI was calculated using the equation (AST × 100)/platelet count (10 9 /L) [46] . The FIB-4 score as calculated using the equation patient [7, 47, 48] .
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RESULTS
Clinical features
The study population had mean age of 51.6 ± 20.6 years and mean body mass index (BMI) of 27.8 ± 6.4 kg/m 2 . The mean FIB-4 score was significantly lower in the treated group compared to the untreated group (2.72 vs 5.99, P = 0.025). A trend of higher levels of serum AST and ALT levels at the time of MRE and liver biopsy was found in the untreated group but was not statistically significant. There were no significant differences in BMI, mean LS, APRI, platelet and INR values between two groups (Table 1) .
Histology findings
Liver biopsy was performed within 3 mo of MRE study with a mean interval of 11.7 d (95%CI: 2-76 d). Histological evaluation revealed fibrosis stages of 0, 1, 2, 3 and 4 in 4, 6, 7, 6 and 13 patients, respectively. Fibrosis (≥ F1) was present in 32 patients (88.9%); significant fibrosis (≥ F2) in 27 patients (75%); advanced fibrosis (≥ F3) in 19 patients (52.8%) and cirrhosis (F4) in 13 patients (36.1%). Inflammation grade 0, 1, 2, 3, and 4 in 2, 7, 15, 9 and 3 patients respectively. The distribution of fibrosis stage and inflammation grade between treated and untreated patients was similar
Correlations between histological findings and laboratory tests
Spearman rank correlation analysis showed significant correlation between fibrosis stage and all serum tests except AST and ALT levels ( Table 2) . Both APRI and INR showed significant correlations with inflammation grade. No significant differences in ALT (P = 0.68), AST (P = 0.25), AST/ALT ratio (P = 0.07), and APRI
Histological assessment
Liver biopsy specimens were reviewed and scored by an experienced hepatopathologist who was blinded to patient data and MRE results. Portal-periportal and lobular inflammation activity grade and fibrosis stage were scored according to Batts et al [49] . Fibrosis was staged on a 0-4 scale on Masson Trichome stain. Interface hepatitis was defined as a portal-periportal inflammation score of ≥ 2. Liver fibrosis stage was scored on a 5-point ordinal scale (0, 1, 2, 3, and 4). All patients with liver biopsy evidence of stage 3 (bridging fibrosis) or stage 4 (cirrhosis) were classified as having advanced fibrosis.
MRE
MRE of the liver was performed according to technique described previously [37] . A pneumatic passive driver was placed overlying the liver which transmitted acoustic vibrations generated at 60 Hz to produce propagating shear waves in the liver which were imaged using a standard MRE sequence as described previously [50] . Four slices were obtained through the largest cross section of the liver in each patient. Total acquisition time was approximately 2 min. MRE data were processed by an inversion algorithm installed on the scanner to produce stiffness maps and wave images. Regions of interest were drawn by a single experienced abdominal radiologist over the liver and excluded artifacts, vessels > 3 mm in size, liver edges and fissures. LS levels above 2.5 kPa were interpreted as elevated [33] .
MRI morphologic features
Two radiologists in consensus evaluated the liver on T2-weighted, T1-weighted, diffusion weighted and post gadolinium enhanced MRI images, and the results required consensus. The following features were assessed: (1) liver parenchyma signal: homogeneous, heterogeneous, patchy/segmental; (2) fatty change; (3) parenchymal enhancement: homogeneous, heterogeneous; (4) surface nodularity: absent, equivocal, present; (5) narrowed hepatic veins: yes/no; (6) presence/absence of the following signs: expanded gall bladder fossa sign, increased hilar periportal space (> 10 mm), hepatic notch sign, creeping mesenteric fat sign; (7) splenomegaly; (8) collaterals; (9) caudate-toright lobe liver ratio; (10) modified caudate-to-right lobe liver ratio; and (11) ascites. An overall impression of the presence of cirrhosis was entered as absent, equivocal, or present.
Statistical analyses
Statistical analyses were performed using MedCalc for Windows, version 15.0 (MedCalc Software, Ostend, Belgium). Statistical analysis was performed by one author (Venkatesh SK) experienced in using MedCalc statistical software. Summary statistics are presented as mean ± SD for continuous variables and as (P = 0.09) were found between different stages of fibrosis by the Kruskal-Wallis test. INR values for stage 4 fibrosis were significantly higher than for stage 1 and 2 fibrosis (1.2 vs 1.0, P < 0.05). Total bilirubin levels were different between fibrosis stage 2 and 4 (P = 0.049), and platelet counts were significantly higher in fibrosis stage 0 and 2 than in stage 4 and between fibrosis stage 2 and 3. Fib-4 scores were significantly higher for fibrosis stage 4 than stages 0-2.
Correlations between histological findings and radiological tests
MRE correlated closely with fibrosis stage (r = 0.83, P < 0.001), and it performed better than MRI. The correlation between LS and fibrosis stages remained significant after correction for age and BMI (r = 0.75, P < 0.001), inflammation grade (r = 0.76, P < 0.001), and all laboratory tests (r = 0.68, P < 0.0001). LS was significantly higher in fibrosis stage 4 than stage 0-3; similarly stage 3 had significantly higher stiffness than stages 0-2. There were no significant differences in LS between stages 0-2 ( Figure 2) .
Untreated patients had a slightly higher mean LS as compared to treated patients (3.83 kPa vs 3.7 kPa), but this was not statistically significant. This trend was seen at each fibrosis stage (stage 0, 3.1 kPa vs 2.61 kPa; stage 1, 2.94 kPa vs 2.74 kPa; stage 2, 3.2 kPa vs 2.63 kPa; stage 3, 4.1 kPa vs 3.99 kPa). The only exception was cirrhotic patients where the treated patients had a higher LS compared to the untreated group (6.5 kPa vs 5.9 kPa).
ROC analysis showed that MRE (cut off, 4.1 kPa) predicted advanced fibrosis (≥ stage 3) with 0.97 accuracy (95%CI: 0.85-0.99), 89.5% sensitivity (95%CI: 67%-99%), 100% specificity (95%CI: 80.5%-100%), 100% positive predictive value (PPV, 95%CI: 80.5%-100%), and 89.5% negative predictive value (NPV, 95%CI: 67%-99%) NPV. Similarly, a cutoff of 4.5 kPa predicted cirrhosis with 0.98 accuracy (95%CI: 0.87-1.00), 92.31% sensitivity (95%CI: 85%-99%) and 96% specificity (95%CI: 78%-99.9%), 92.3% PPV (95%CI: 64%-99.8%) and 88% NPV (95%CI: 68.8%-97.5%).
Comparison between radiological tests and laboratory tests
Comparison of ROC curves for MRE and laboratory tests showed that MRE performed significantly better than ALT, AST, AST/ALT, APRI, FIB-4, INR and platelet counts for the detection of advanced fibrosis (Table  3 , Figure 3A ). FIB-4 performed better than AST, ALT and APRI for detecting advanced fibrosis, and all the laboratory tests performed better than the serum ALT level in making this distinction. Similarly for cirrhosis, MRE performed significantly better than all laboratory tests (Table 3 , Figure 3B ). FIB-4 only performed better than the serum ALT level in detecting cirrhosis, and the serum ALT level was worse than all other laboratory tests in making this distinction. We also analyzed diagnostic performance of MRE and laboratory tests for two study groups. In the untreated group of 17 patients MRE performance was better than laboratory 
DISCUSSION
A non-invasive, accurate method of detecting advanced fibrosis and cirrhosis in patients with AIH is required to assess disease progression during therapy, anticipate complications of cirrhosis, and evaluate the risk of HCC. Our study demonstrates high accuracy of MRE in detecting advanced fibrosis and cirrhosis in patients with 
A B
AIH, and its superiority to laboratory assessment and conventional MRI. Our findings are consistent with other studies that demonstrate greater diagnostic accuracy of MRE over laboratory assessment in detecting advanced fibrosis and cirrhosis in patients with diverse chronic liver diseases [34, 38, 40, 50, 51] . Furthermore, our study indicates that the laboratory and histological indices of liver inflammation do not compromise the accuracy of MRE in assessing hepatic fibrosis in AIH. Untreated patients showed mildly higher LS as compared to treated patients which was not statistically significant, likely related to the presence of inflammation in the untreated group, and the subset of untreated AIH patients did have higher inflammation grades. This finding suggests that hepatic inflammation could have an impact on determinations of LS by MRE, and it was similar to that in patients with chronic viral hepatitis in whom the presence of chronic inflammation has been shown to increase LS by MRE [52] . In our study, there was no significant difference in the distribution of inflammation grades between the treated and untreated groups, and fibrosis stages were detected with similar accuracy in the treated and untreated patients. Our study also showed that cirrhotic livers in treated patients had higher mean stiffness as compared to cirrhotic livers in untreated patients. The exact reason is not known, however it is possible that the fibrosis content in treated patients is likely to be more as the duration of disease was longer in these patients. This needs to be confirmed in studies with a larger number of participants.
Recent studies performed with TE and ARFI in AIH have shown that both techniques are useful in assessment of significant fibrosis and cirrhosis in AIH. In one study with nearly 100 patients, Hartl et al [26] showed excellent diagnostic performance of TE for diagnosis of cirrhosis. They also showed that liver inflammation has a major impact on LS in first few months of AIH treatment and its diagnostic performance improves after 6 mo of immunosuppression treatment. In our study we also showed that untreated patients had higher stiffness compared to treated patients. In addition the diagnostic performance of MRE in treated patients was slightly better than that in untreated patients, however the numbers of patients in our study groups are too small to draw conclusions. In another study of only 15 patients, Efe et al [53] showed that ARFI is able to accurately differentiate significant fibrosis from non-significant fibrosis. There are no comparison studies between MRE, TE and ARFI and future studies combining all three modalities may be useful for determining their utility in different clinical scenarios. Our study has limitations. First, the study was retrospective. This was unavoidable as patients frequently received treatment at outside medical centers. This also precludes assessment of the time interval between initial diagnosis and treatment to liver biopsy and MRE. Second, our sample size is small because the timing of liver tissue examinations and the performance of MRE was variable, and overlap syndromes were excluded. Third, the reference standard was histological assessment, which is limited by sampling error and inter-observer variability [8] [9] [10] . This was mitigated by applying a standardized scoring system for fibrosis and inflammation, requiring all specimens to be stained for fibrosis, and having each tissue sample re-reviewed by a pathologist specialized in autoimmune liver diseases [54] . Fourth, our study group comprised treated and untreated patients, which was unavoidable due to the rarity of AIH and retrospective nature of the study. Fifth, patients were assessed at varying intervals during the course of their disease, and were not studied sequentially to assess for detection of small gradations of change.
MRE is a non-invasive imaging-based biomarker with superior diagnostic accuracy for detecting advanced fibrosis and cirrhosis in patients with AIH compared to conventional laboratory and MRI assessment. MRE may become useful as a non-invasive tool for staging fibrosis in AIH, evaluating response to treatment, and decision-making regarding drug administration, dose adjustment, and duration of therapy. Our study provides a foundation for future prospective studies that evaluate the role of MRE to detect changes in LS that can be used safely and repeatedly in patients with AIH of all ages, habitus, and disease severity. 
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Background
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease which can progress to advanced fibrosis and cirrhosis. Histological evaluation is the gold standard for assessing hepatic fibrosis, but is suboptimal for monitoring disease progression due to its invasiveness, sampling error, and inter-observer variation. A non-invasive, accurate method of detecting advanced fibrosis and cirrhosis in patients with AIH is required to assess disease progression during therapy, anticipate complications of cirrhosis, and evaluate the risk of hepatocellular carcinoma. Magnetic resonance elastography (MRE) has the potential to fulfill this function.
Research frontiers
MRE is a non-invasive imaging-based biomarker that has far reaching applications in the diagnosis, management, and treatment of patients with AIH.
Innovations and breakthroughs
This study provides a foundation for future prospective studies that evaluate the role of MRE to detect changes in liver stiffness that can be used safely and repeatedly in patients with AIH of all ages, habitus, and disease severity.
Applications
MRE may become useful as a non-invasive tool for staging fibrosis in AIH, evaluating response to treatment, and decision-making regarding drug administration, dose adjustment, and duration of therapy.
Terminology
MRE is a magnetic resonance imaging based technique that non-invasively assesses tissue stiffness.
Peer-review
These findings represent a first effort at defining the role of MRE in the evaluation of AIH. There is robust information supporting the usefulness of this technique in accurately assessing liver fibrosis in other liver diseases, such as hepatitis C, hepatitis B and non-alcoholic fatty liver disease.
